Clinical trials: Esophagogastric Junction
Gastric Carcinoma, Gastroesophageal Junction Adenocarcinoma
Telehealth for the Self-Management of Dietary Quality of Life in Patients After Stomach Cancer Surgery
This clinical trial test whether taking part in a diet support intervention will help with patients nutrition and quality of life after surgery for esophagus or stomach cancer.
- Trial name
- NCT05203627
- Testing
- Best Practice, Questionnaire Administration, Telemedicine Visit
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- City of Hope Medical Center
Esophageal Cancer
A Biomarker-driven Therapeutic Strategy for Esophageal Cancer Chemoradiotherapy in Patients With Resectable Adenocarcinoma of the ESophagus and Esophagogastric Junction
Preoperative chemoradiotherapy followed by surgery has been accepted as the standard of care for resectable adenocarcinoma of the esophagus and esophagogastric junction (EGJ).
- Trial name
- BoRgES (NCT04269083)
- Testing
- BIRC3
- Volunteers
- 128 people
- Sponsor
- Azienda Ospedaliera Universitaria Integrata Verona
Advanced Gastric Cancer Adenocarcinoma of Esophagogastric Junction
mFOLFOX Versus mFOLFIRI Versus FOLFPTX as First-line Treatment in AGC or EGJA
The aim of this study was to compare the efficacy and safety of mFOLFOX, mFOLFIRI and FOLFPTX as first-line treatment in AGC or EGJA.
- Trial name
- NCT03045770
- Testing
- Fluorouracil, Oxaliplatin, Irinotecan
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Fujian Cancer Hospital
Urinary Bladder Cancer, Melanoma
MAGE-A4ᶜ¹º³²T for Multi-Tumor
This study will investigate the safety and tolerability of MAGE-A4ᶜ¹º³²T cell therapy in subjects who have the appropriate HLA-A2 tissue marker and whose urinary bladder, melanoma, head and neck, ovarian, non-small cell lung…
- Conditions
- Urinary Bladder Cancer, Melanoma, Head and Neck Cancer, Ovarian Cancer
- Trial name
- NCT03132922
- Testing
- Autologous genetically modified MAGE-A4ᶜ¹º³²T cells, Autologous genetically modified MAGE-A4c1032T cells combined with low dose radiation
- Where
- 11 sites in United States, Canada
- Volunteers
- 71 people
- Sponsor
- USWM CT, LLC
Esophagus Adenocarcinoma, Esophagus Squamous Cell Carcinoma
Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal Cancer
Esophageal cancer, which has a low 5-year overall survival rate for all stages (<20%) , is increasing in incidence. Previous studies have shown that the Hedgehog (Hh) and AKT signaling pathways are activated in a significant…
- Conditions
- Esophagus Adenocarcinoma, Esophagus Squamous Cell Carcinoma, Gastroesophageal Junction Adenocarcinoma
- Trial name
- NCT04018872
- Testing
- Itraconazole
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- Dallas VA Medical Center
Gastric Cancer, Gastroesophageal Junction Cancer
A Study of Treatment Patterns in HER2-positive Unresectable and Advanced Gastric/ Gastroesophageal Junction Cancer in China
This study will be conducted to retrospectively evaluate the treatment patterns in first-line, second-line, and subsequent lines of therapy for HER2-positive Gastric Cancer/Gastroesophageal Junction Cancer (GC/GEJC) patients.
- Trial name
- REHEARSAL (NCT06585501)
- Testing
- No drug
- Where
- 9 sites in China
- Volunteers
- 805 people
- Sponsor
- Daiichi Sankyo
Gastric Cancer, Gastric Adenocarcinoma
A Study of DKN-01 in Combination With Tislelizumab ± Chemotherapy in Patients With Gastric or Gastroesophageal Cancer
A Phase 2, Multicenter, Open-Label Study of DKN-01 in Combination with Tislelizumab ± Chemotherapy as First-Line or Second-Line Therapy in Adult Patients with Inoperable, Locally Advanced or Metastatic Gastric or Gastroesophageal…
- Conditions
- Gastric Cancer, Gastric Adenocarcinoma, GastroEsophageal Cancer
- Trial name
- DisTinGuish (NCT04363801)
- Testing
- DKN-01 300mg, DKN-01 600mg, DKN-01 400mg
- Where
- 48 sites in United States, Germany and 1 more
- Volunteers
- 247 people
- Sponsor
- Leap Therapeutics, Inc.
Advanced Esophageal Adenocarcinoma, Advanced Gastric Adenocarcinoma
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial
This phase II/III trial compares the addition of nivolumab to the usual treatment of paclitaxel and ramucirumab to paclitaxel and ramucirumab alone in treating patients with gastric or esophageal adenocarcinoma that may have…
- Conditions
- Advanced Esophageal Adenocarcinoma, Advanced Gastric Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Clinical Stage II Esophageal Adenocarcinoma AJCC v8
- Trial name
- NCT06203600
- Testing
- Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging
- Where
- 378 sites in United States
- Volunteers
- 224 people
- Sponsor
- National Cancer Institute (NCI)
Gastric Adenocarcinoma, Adenocarcinoma of the Esophagogastric Junction
Sino-Russian Comparison of Outcomes After Proximal Gastrectomy With Double-Tract Reconstruction
This two-center retrospective observational cohort study compares Chinese and Russian patients who underwent curative proximal gastrectomy with double-tract reconstruction for proximal gastric adenocarcinoma or Siewert type…
- Trial name
- RUSCHI-DTR (NCT07800819)
- Testing
- Proximal gastrectomy with double-tract reconstruction
- Where
- 2 sites in China, Russia
- Volunteers
- 250 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Gastric Cancer
T900607 in Treating Patients With Gastroesophageal Junction Cancer
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of T900607 in treating patients who have…
- Trial name
- NCT00054249
- Testing
- T900607
- Where
- United States
- Sponsor
- University Hospitals Seidman Cancer Center
Neoplasms, Lymphoma
A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 in Patients With Advanced or Refractory Solid Tumors or Lymphoma
The purpose of this study is to determine a dose for future development and to evaluate the safety, pharmacokinetics, pharmacodynamics, and efficacy profiles of JNJ-42756493 in Japanese and other Asian patients with advanced or…
- Conditions
- Neoplasms, Lymphoma, Adenocarcinoma, Esophagogastric Junction
- Trial name
- NCT01962532
- Testing
- Part 1: JNJ-42756493, Part 2: JNJ-42756493
- Where
- 3 sites in Japan
- Volunteers
- 19 people
- Sponsor
- Janssen Research & Development, LLC
Morbid Obesity
Prospective Study of the Impact of Sleeve Gastrectomy on Gastro-esophageal Junction Function
Improved results for sleeve gastrectomy could be possible if more was known about the surgical / mechanical factors that affect outcome.
- Trial name
- FFSI (NCT01980420)
- Testing
- Laparoscopic sleeve gastrectomy
- Where
- France
- Volunteers
- 35 people
- Sponsor
- IHU Strasbourg
Esophageal Cancer, Esophagogastric Junction Cancer
ChemoRadiation And Tislelizumab for Esophageal/EGJ Cancer
This study aims to determine the effects of chemoradiation and Tislelizumab on Esophageal/EGJ Cancer before and after surgery.
- Trial name
- CRATER (NCT05245760)
- Testing
- Intravenous Tislelizumab, Chemotherapy, Fractionated radiation
- Where
- United States
- Sponsor
- Zhonglin Hao
GEJ Adenocarcinoma
Retlirafusp Alfa Injection Combined Chemotherapy for Perioperative Treatment of Esophagogastric Junction Adenocarcinoma: A Single-Arm, Phase II Study of Safety and Efficacy
This is a prospective, phase II, exploratory clinical trial. The study aims to evaluate the efficacy and safety of Retlirafusp alfa Injection in combination with chemotherapy during the perioperative period for the treatment of…
- Trial name
- NCT07493382
- Testing
- Retlirafusp alfa Injection
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8
Paclitaxel for the Treatment of Gastric or Gastroesophageal Cancer
This phase I trial studies the side effects and best dose of paclitaxel for the treatment of gastric or gastroesophageal cancer.
- Conditions
- Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastric Cancer AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8
- Trial name
- NCT04220827
- Testing
- Paclitaxel
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- M.D. Anderson Cancer Center
Advanced Solid Cancers
A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9
The main goal of this study is to evaluate the safety of BNT329 and to identify the best dose of BNT329. This will be done by measuring the number of side effects that participants experience and how severe they are.
- Trial name
- NCT07186842
- Testing
- BNT329, CA19-9-targeting monoclonal antibody
- Where
- 18 sites in United States, Australia and 3 more
- Volunteers
- 245 people
- Sponsor
- BioNTech SE
Gastroesophageal Adenocarcinoma
The Sequential Combination of FOLFOX and Toripalimab for Perioperative Immuno-Oncology Therapy of HER2-negative Adenocarcinoma of the Esophagogastric Junction (Siewert I/II):
The addition of immunotherapy to chemotherapy improves outcomes in patients with HER2-negative gastroesophageal adenocarcinoma (GEA), and investigators aim to explore its role in the perioperative setting.
- Trial name
- SCORPIO (NCT05986227)
- Testing
- toripalimab FOLFOX
- Volunteers
- 126 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Gastric Cancer
Toripalimab Combined With FLOT Neoadjuvant Chemotherapy in Patients With Resectable Gastric Cancer
Gastric cancer is one of the most common malignant tumors of the digestive tract. Gastric cancer patients diagnosed for the first time in China have a higher proportion of advanced stages and a higher postoperative metastasis…
- Trial name
- NCT04354662
- Testing
- Toripalimab, Docetaxel, Fluorouracil
- Where
- China
- Volunteers
- 51 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Advanced Gastric Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma
Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal Adenocarcinoma
This early phase I trial studies the effect of pembrolizumab and lenvatinib in treating patients with gastroesophageal adenocarcinoma that has spread to other places in the body (advanced/metastatic) or cannot be removed by…
- Conditions
- Advanced Gastric Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
- Trial name
- NCT05041153
- Testing
- Lenvatinib, Pembrolizumab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- M.D. Anderson Cancer Center
Melanoma, Non Small Cell Lung Cancer
Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors
AI-061 is a co-formulation drug product (DP) consisting of 1:1 ratio mix of AI-025, an anti-PD-1 antibody, and ONC-392, an anti-CTLA-4 antibody.
- Conditions
- Melanoma, Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, High Grade Serous Adenocarcinoma of Ovary
- Trial name
- PRESERVE-009 (NCT05858736)
- Testing
- AI-061
- Where
- 5 sites in Australia
- Volunteers
- 18 people
- Sponsor
- OncoC4, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.